Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-08046037 |
| Synonyms | |
| Therapy Description |
PF-08046037 (SGN-PDL1iT) is an immune-stimulating antibody conjugate comprising an antibody targeting CD274 (PD-L1) linked to a TLR7 agonist, which potentially induces antitumor immune activity (Cancer Res (2025) 85 (8_Supplement_1): 5840). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-08046037 | PF08046037|PF 08046037 | PF-08046037 (SGN-PDL1iT) is an immune-stimulating antibody conjugate comprising an antibody targeting CD274 (PD-L1) linked to a TLR7 agonist, which potentially induces antitumor immune activity (Cancer Res (2025) 85 (8_Supplement_1): 5840). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06974734 | Phase I | PF-08046037 PF-06801591 + PF-08046037 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | Recruiting | USA | 1 |